溶血栓药物在急性脑梗死中的应用进展

Advance of thrombolytic agents in treatment of acute brain infarction

脑梗死是导致人类致残和死亡的主要疾病之一,在发生脑梗死的超急性期,积极给予溶栓治疗,开通闭塞的血管,恢复缺血区的再灌注是治疗的关键。目前只有重组组织型纤溶酶原激活剂(rt-PA)被FDA批准应用于急性脑梗死的溶栓治疗,其他的许多药物如瑞替普酶,替奈普酶,去氨普酶、安克洛酶等在脑梗死治疗应用方面正在探索中。本文将针对上述几种主要的溶血栓药物及其已经开展的相关临床研究进行论述。

Stroke acute therapy in order to is a common cause of morbidity and mortality in the world. It is improve individual outcomes. Recombinant tissue-type plasminog important to provide en activator （rt-PA） is, at present, the only approved drug by FDA for the treatment of acute brain infarction. Other thrombolytic agents, such as reteplase, TNK-PA, DSPA, ancrod, are being studied. This article will review the main thrombolytic agents and the trails performed thus far.